Tien Liang Biotech (4127) reported revenue of NT$44.1 million for Oct 2026, +2.3% year on year and -22.6% from the previous month. Revenue for Jan–Oct 2026 was NT$597.7 million (+40.7% year on year).
Year-on-year revenue growth: 21 months in a row. →
In Oct 2026, it ranked No. 103 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$44.1 million | +2.3% | -22.6% |
| Sep 2026 | NT$57 million | +10.9% | +4.0% |
| Aug 2026 | NT$54.8 million | +40.8% | -7.0% |
| Jul 2026 | NT$58.9 million | +25.2% | +6.3% |
| Jun 2026 | NT$55.4 million | +41.4% | -8.5% |
| May 2026 | NT$60.6 million | +27.0% | -11.9% |
| Apr 2026 | NT$68.7 million | +66.8% | +3.0% |
| Mar 2026 | NT$66.7 million | +47.1% | -14.4% |
| Feb 2026 | NT$77.9 million | +139.1% | +45.4% |
| Jan 2026 | NT$53.6 million | +37.1% | +21.5% |
| Dec 2025 | NT$44.1 million | +75.0% | -0.8% |
| Nov 2025 | NT$44.4 million | +35.0% | +3.1% |
| Oct 2025 | NT$43.1 million | +47.1% | -16.1% |
| Sep 2025 | NT$51.4 million | +70.5% | +32.1% |
| Aug 2025 | NT$38.9 million | +19.4% | -17.4% |
| Jul 2025 | NT$47.1 million | +35.5% | +20.0% |
| Jun 2025 | NT$39.2 million | +56.9% | -17.7% |
| May 2025 | NT$47.7 million | +60.2% | +15.7% |
| Apr 2025 | NT$41.2 million | +44.8% | -9.1% |
| Mar 2025 | NT$45.4 million | +70.8% | +39.1% |
| Feb 2025 | NT$32.6 million | +4.3% | -16.6% |
| Jan 2025 | NT$39.1 million | -28.9% | +55.1% |
| Dec 2024 | NT$25.2 million | -31.2% | -23.4% |
| Nov 2024 | NT$32.9 million | -9.3% | +12.3% |
| Oct 2024 | NT$29.3 million | -35.2% | -2.7% |
Jan–Oct 2026 cumulative: NT$597.7 million (+40.7% YoY)
Other Biotech & Medical companies
Compare with peers: Tien Liang Biotech vs PEC / Tien Liang Biotech vs Lotus Pharm / Tien Liang Biotech vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16